Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2012, Article ID 821579, 7 pages
http://dx.doi.org/10.1155/2012/821579
Review Article

Gamma Knife Radiosurgery for Acromegaly

1Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143-0112, USA
2California Center for Pituitary Disorders, University of California, San Francisco, San Francisco, CA 94143-0350, USA

Received 10 September 2011; Revised 18 November 2011; Accepted 23 November 2011

Academic Editor: Anil K. Agarwal

Copyright © 2012 John D. Rolston and Lewis S. Blevins Jr. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. J. Stapleton, C. Y. Liu, and M. H. Weiss, “The role of stereotactic radiosurgery in the multimodal management of growth hormone-secreting pituitary adenomas,” Neurosurgical Focus, vol. 29, no. 4, article E11, 2010. View at Google Scholar
  2. I. Yang, W. Kim, A. De Salles, and M. Bergsneider, “A systematic analysis of disease control in acromegaly treated with radiosurgery,” Neurosurgical Focus, vol. 29, no. 4, article E13, 2010. View at Google Scholar
  3. N. C. Rowland and M. K. Aghi, “Radiation treatment strategies for acromegaly,” Neurosurgical Focus, vol. 29, no. 4, article E12, 2010. View at Google Scholar
  4. A. S. Fauci, Harrison's Principles of Internal Medicine, Edited by A. S. Fauci, etal, McGraw-Hill Medical, 2008.
  5. C. Berg, S. Petersenn, H. Lahner et al., “Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 8, pp. 3648–3656, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. I. M. Holdaway and C. Rajasoorya, “Epidemiology of acromegaly,” Pituitary, vol. 2, no. 1, pp. 29–41, 1999. View at Google Scholar · View at Scopus
  7. A. Fernandez, N. Karavitaki, and J. A. H. Wass, “Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK),” Clinical Endocrinology, vol. 72, no. 3, pp. 377–382, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. A. F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M. A. Tichomirowa, and A. Beckers, “High prevalence of pituitary adenomas: a cross-sectional study in the province of Liège, Belgium,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 12, pp. 4769–4775, 2006. View at Publisher · View at Google Scholar · View at PubMed
  9. H. J. Schneider, C. Sievers, B. Saller, H. U. Wittchen, and G. K. Stalla, “High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels,” Clinical Endocrinology, vol. 69, no. 3, pp. 432–435, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. M. Fleseriu, J. B. Delashaw, and D. M. Cook, “Acromegaly: a review of current medical therapy and new drugs on the horizon,” Neurosurgical Focus, vol. 29, no. 4, article E15, 2010. View at Google Scholar
  11. E. R. Laws, “Surgery for acromegaly: evolution of the techniques and outcomes,” Reviews in Endocrine and Metabolic Disorders, vol. 9, no. 1, pp. 67–70, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. P. Grass, P. Marbach, C. Bruns, and I. Lancranjan, “Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships,” Metabolism, vol. 45, no. 1, pp. 27–30, 1996. View at Google Scholar · View at Scopus
  13. O. Alexopoulou, P. Abrams, J. Verhelst et al., “Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR,” European Journal of Endocrinology, vol. 151, no. 3, pp. 317–324, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. S. G. Ashwell, J. S. Bevan, O. M. Edwards et al., “The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR,” European Journal of Endocrinology, vol. 150, no. 4, pp. 473–480, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. C. L. Ronchi, M. Boschetti, E. C. D. Uberti et al., “Efficacy of a slow-release formulation of lanreotide (Autogel 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study,” Clinical Endocrinology, vol. 67, no. 4, pp. 512–519, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. M. Andries, D. Glintborg, A. Kvistborg, C. Hagen, and M. Andersen, “A 12-month randomized crossover study on the effects of Lanreotide Autogel and Octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly,” Clinical Endocrinology, vol. 68, no. 3, pp. 473–480, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. J. S. Bevan, “Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 3, pp. 1856–1863, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. R. Abs, J. Verhelst, D. Maiter et al., “Cabergoline in the treatment of acromegaly: a study in 64 patients,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 2, pp. 374–378, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Sandret, P. Maison, and P. Chanson, “Place of cabergoline in acromegaly: a meta-analysis,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 5, pp. 1327–1335, 2011. View at Publisher · View at Google Scholar · View at PubMed
  20. S. Manjila, O. C. Wu, F. R. Khan, M. M. Khan, B. M. Arafah, and W. R. Selman, “Pharmacological management of acromegaly: a current perspective.,” Neurosurgical Focus, vol. 29, no. 4, article E14, 2010. View at Google Scholar
  21. S. W. J. Lamberts, P. Utterlinden, and T. Verleun, “Relationship between growth hormone and somatomedin-C levels in untreated acromegaly, after surgery and radiotherapy and during medical therapy with sandostatin (SMS 201-995),” European Journal of Clinical Investigation, vol. 17, no. 4, pp. 354–359, 1987. View at Google Scholar · View at Scopus
  22. A. K. Fløgstad, J. Halse, P. Grass et al., “A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly,” Journal of Clinical Endocrinology and Metabolism, vol. 79, no. 2, pp. 461–465, 1994. View at Publisher · View at Google Scholar
  23. P. Mattar, M. R. Alves Martins, and J. Abucham, “Short-and long-term efficacy of combined cabergoline and octreotide treatment in controlling IGF-I levels in acromegaly,” Neuroendocrinology, vol. 92, no. 2, pp. 120–127, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. R. S. Jallad and M. D. Bronstein, “Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide,” Neuroendocrinology, vol. 90, no. 1, pp. 82–92, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. P. J. Trainer, W. M. Drake, L. Katznelson et al., “Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant,” The New England Journal of Medicine, vol. 342, no. 16, pp. 1171–1177, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. I. Schreiber, M. Buchfelder, M. Droste et al., “Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study,” European Journal of Endocrinology, vol. 156, no. 1, pp. 75–82, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. J. H. Buhk, S. Jung, M. N. Psychogios et al., “Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 2, pp. 552–558, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. M. Marazuela, A. E. Paniagua, M. D. Gahete et al., “Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 2, pp. E251–E259, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. H. Biering, B. Saller, J. Bauditz et al., “Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis,” European Journal of Endocrinology, vol. 154, no. 2, pp. 213–220, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. B.G. Haffty and L. D. Wilson, Handbook of Radiation Oncology : Basic Principles and Clinical Protocols, Jones & Bartlett, 2009.
  31. F. M. Khan, The Physics of Radiation Therapy, Lippincott Williams & Wilkins, 2010.
  32. M. P. Mehta, “The physical, biologic, and clinical basis of radiosurgery,” Current Problems in Cancer, vol. 19, no. 5, pp. 265–329, 1995. View at Google Scholar · View at Scopus
  33. A. Giustina, P. Chanson, M. D. Bronstein et al., “A consensus on criteria for cure of acromegaly,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 7, pp. 3141–3148, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. E. O. Vik-Mo, M. Øksnes, P. H. Pedersen et al., “Gamma knife stereotactic radiosurgery for acromegaly,” European Journal of Endocrinology, vol. 157, no. 3, pp. 255–263, 2007. View at Publisher · View at Google Scholar · View at PubMed
  35. N. M. Barbaro, M. Quigg, D. K. Broshek et al., “A multicenter, prospective pilot study of gamma knife radiosurgery for mesial temporal lobe epilepsy: seizure response, adverse events, and verbal memory,” Annals of Neurology, vol. 65, no. 2, pp. 167–175, 2009. View at Publisher · View at Google Scholar · View at PubMed
  36. I. Yang, D. Aranda, S. J. Han et al., “Hearing preservation after stereotactic radiosurgery for vestibular schwannoma: a systematic review,” Journal of Clinical Neuroscience, vol. 16, no. 6, pp. 742–747, 2009. View at Publisher · View at Google Scholar · View at PubMed
  37. A. M. Landolt, D. Haller, N. Lomax et al., “Octreotide may act as a radioprotective agent in acromegaly,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 3, pp. 1287–1289, 2000. View at Publisher · View at Google Scholar
  38. B. E. Pollock, J. T. Jacob, P. D. Brown, and T. B. Nippoldt, “Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission,” Journal of Neurosurgery, vol. 106, no. 5, pp. 833–838, 2007. View at Publisher · View at Google Scholar · View at PubMed
  39. B. E. Pollock, T. B. Nippoldt, S. L. Stafford, R. L. Foote, and C. F. Abboud, “Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization,” Journal of Neurosurgery, vol. 97, no. 3, pp. 525–530, 2002. View at Google Scholar
  40. T. Kobayashi, Y. Mori, Y. Uchiyama, Y. Kida, and S. Fujitani, “Long-term results of gamma knife surgery for growth hormone-producing pituitary adenoma: is the disease difficult to cure?” Journal of Neurosurgery, vol. 102, pp. 119–123, 2005. View at Publisher · View at Google Scholar
  41. B. A. Tinnel, M. A. Henderson, T. C. Witt et al., “Endocrine response after gamma knife-based stereotactic radiosurgery for secretory pituitary adenoma,” Stereotactic and Functional Neurosurgery, vol. 86, no. 5, pp. 292–296, 2008. View at Publisher · View at Google Scholar · View at PubMed
  42. Y. Iwai, K. Yamanaka, M. Yoshimura, I. Kawasaki, K. Yamagami, and K. Yoshioka, “Gamma knife radiosurgery for growth hormone-producing adenomas,” Journal of Clinical Neuroscience, vol. 17, no. 3, pp. 299–304, 2010. View at Publisher · View at Google Scholar · View at PubMed
  43. C. L. Ronchi, R. Attanasio, E. Verrua et al., “Efficacy and tolerability of gamma knife radiosurgery in acromegaly: a 10-year follow-up study,” Clinical Endocrinology, vol. 71, no. 6, pp. 846–852, 2009. View at Publisher · View at Google Scholar · View at PubMed
  44. F. M. Swords, J. P. Monson, G. M. Besser et al., “Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy,” European Journal of Endocrinology, vol. 161, no. 6, pp. 819–828, 2009. View at Publisher · View at Google Scholar · View at PubMed
  45. H. Wan, O. Chihiro, and S. Yuan, “MASEP gamma knife radiosurgery for secretory pituitary adenomas: experience in 347 consecutive cases,” Journal of Experimental and Clinical Cancer Research, vol. 28, no. 1, article 36, 2009. View at Publisher · View at Google Scholar · View at PubMed
  46. J. Jagannathan, C. P. Yen, N. Pouratian, E. R. Laws, and J. P. Sheehan, “Stereotactic radiosurgery for pituitary adenomas: a comprehensive review of indications, techniques and long-term results using the Gamma Knife,” Journal of Neuro-Oncology, vol. 92, no. 3, pp. 345–356, 2009. View at Publisher · View at Google Scholar · View at PubMed
  47. M. Losa, L. Gioia, P. Picozzi et al., “The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 7, pp. 2546–2552, 2008. View at Publisher · View at Google Scholar · View at PubMed
  48. B. E. Pollock, P. D. Brown, T. B. Nippoldt, and W. F. Young, “Pituitary tumor type affects the chance of biochemical remission after radiosurgery of hormone-secreting pituitary adenomas,” Neurosurgery, vol. 62, no. 6, pp. 1271–1278, 2008. View at Publisher · View at Google Scholar · View at PubMed
  49. J. Ježková, J. Marek, V. Hána et al., “Gamma knife radiosurgery for acromegaly—long-term experience,” Clinical Endocrinology, vol. 64, no. 5, pp. 588–595, 2006. View at Publisher · View at Google Scholar · View at PubMed
  50. F. Castinetti, D. Taieb, J. M. Kuhn et al., “Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 8, pp. 4483–4488, 2005. View at Publisher · View at Google Scholar · View at PubMed
  51. R. Attanasio, P. Epaminonda, E. Motti et al., “Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 7, pp. 3105–3112, 2003. View at Publisher · View at Google Scholar
  52. J. Y. Choi, J. H. Chang, J. W. Chang, Y. Ha, Y. G. Park, and S. S. Chung, “Radiological and hormonal responses of functioning pituitary adenomas after Gamma Knife radiosurgery,” Yonsei Medical Journal, vol. 44, no. 4, pp. 602–607, 2003. View at Google Scholar
  53. J. A. Jane Jr., M. L. Vance, C. J. Woodburn, and E. R. Laws, “Stereotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach,” Neurosurgical Focus, vol. 14, no. 5, article e12, 2003. View at Google Scholar
  54. Z. Petrovich, C. Yu, S. L. Giannotta et al., “Gamma knife radiosurgery for pituitary adenoma: early results,” Neurosurgery, vol. 53, no. 1, pp. 51–61, 2003. View at Google Scholar
  55. H. Ikeda, H. Jokura, and T. Yoshimoto, “Transsphenoidal surgery and adjuvant gamma knife treatment for growth hormone-secreting pituitary adenoma,” Journal of Neurosurgery, vol. 95, no. 2, pp. 285–291, 2001. View at Google Scholar
  56. S. Fukuoka, T. Ito, M. Takanashi, A. Hojo, and H. Nakamura, “Gamma knife radiosurgery for growth hormone-secreting pituitary adenomas invading the cavernous sinus,” Stereotactic and Functional Neurosurgery, vol. 76, no. 3-4, pp. 213–217, 2001. View at Publisher · View at Google Scholar
  57. M. Izawa, M. Hayashi, K. Nakaya et al., “Gamma knife radiosurgery for pituitary adenomas,” Journal of Neurosurgery, vol. 93, no. 3, supplement, pp. 19–22, 2000. View at Google Scholar
  58. M. Shin, H. Kurita, T. Sasaki et al., “Stereotactic radiosurgery for pituitary adenoma invading the cavernous sinus,” Journal of Neurosurgery, vol. 93, no. 3, supplement, pp. 2–5, 2000. View at Google Scholar
  59. N. Zhang, L. Pan, J. Dai et al., “Gamma Knife radiosurgery as a primary surgical treatment for hypersecreting pituitary adenomas,” Stereotactic and Functional Neurosurgery, vol. 75, no. 2-3, pp. 123–128, 2000. View at Publisher · View at Google Scholar
  60. H. K. Inoue, H. Kohga, M. Hirato et al., “Pituitary adenomas treated by microsurgery with or without Gamma Knife surgery: experience in 122 cases,” Stereotactic and Functional Neurosurgery, vol. 72, supplement 1, pp. 125–131, 1999. View at Google Scholar
  61. M. S. Kim, S. I. Lee, and J. H. Sim, “Gamma Knife radiosurgery for functioning pituitary microadenoma,” Stereotactic and Functional Neurosurgery, vol. 72, supplement 1, pp. 119–124, 1999. View at Google Scholar
  62. S. H. Kim, R. Huh, J. W. Chang, Y. G. Park, and S. S. Chung, “Gamma Knife radiosurgery for functioning pituitary adenomas,” Stereotactic and Functional Neurosurgery, vol. 72, supplement 1, pp. 101–110, 1999. View at Google Scholar
  63. M. Mokry, S. Ramschak-Schwarzer, J. Simbrunner, J. C. Ganz, and G. Pendl, “A six year experience with the postoperative radiosurgical management of pituitary adenomas,” Stereotactic and Functional Neurosurgery, vol. 72, supplement 1, pp. 88–100, 1999. View at Google Scholar
  64. Y. J. Lim, W. Leem, T. S. Kim, B. A. Rhee, and G. K. Kim, “Four years' experiences in the treatment of pituitary adenomas with Gamma Knife radiosurgery,” Stereotactic and Functional Neurosurgery, vol. 70, supplement 1, pp. 95–109, 1998. View at Publisher · View at Google Scholar
  65. R. Martinez et al., “Pituitary tumors and gamma knife surgery. Clinical experience with more than two years of follow-up,” Stereotactic and Functional Neurosurgery, vol. 70, supplement 1, pp. 110–1118, 1998. View at Google Scholar
  66. Morange-Ramosa, J. Régis, H. Dufour et al., “Short-term endocrinological results after Gamma Knife surgery of pituitary adenomas,” Stereotactic and Functional Neurosurgery, vol. 70, supplement 1, pp. 127–138, 1998. View at Publisher · View at Google Scholar
  67. L. Pan, N. Zhang, E. Wang, B. Wang, and W. Xu, “Pituitary adenomas: the effect of Gamma Knife radiosurgery on tumor growth and endocrinopathies,” Stereotactic and Functional Neurosurgery, vol. 70, supplement 1, pp. 119–126, 1998. View at Publisher · View at Google Scholar
  68. Y. G. Park, J. W. Chang, E. Y. Kim, and S. S. Chung, “Gamma knife surgery in pituitary microadenomas,” Yonsei Medical Journal, vol. 37, no. 3, pp. 165–173, 1996. View at Google Scholar